Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HARRY PAUL ERBA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1508942566
CMS profile
158675
Location
ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$187,022.43

138 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Incyte Corporation $78,041.95 69
Daiichi Sankyo Inc. $38,680.14 31
SERVIER PHARMACEUTICALS LLC $34,129.20 15
Syndax Pharmaceuticals, Inc. $20,768.82 15
TAIHO ONCOLOGY, INC. $6,471.79 3
Sumitomo Pharma America, Inc. $6,020.00 2
Rigel Pharmaceuticals, Inc. $2,910.53 3

Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HARRY PAUL ERBA

NPI 1508942566 · CMS profile ID 158675

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508942566?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HARRY PAUL ERBA, NPI 1508942566, CMS profile ID 158675. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508942566?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). HARRY PAUL ERBA, NPI 1508942566, CMS profile ID 158675. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508942566?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
HARRY PAUL ERBA, NPI 1508942566, CMS profile ID 158675, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1508942566?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

138 matching records · $187,022.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 138 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 138.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $113.0009/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226138600 CMS
Incyte Corporation $249.0009/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225971833 CMS
Rigel Pharmaceuticals, Inc. $2,740.0009/13/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1247366551 CMS
Daiichi Sankyo Inc. $4,116.0009/10/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1197095199 CMS
Syndax Pharmaceuticals, Inc. $136.1209/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238990946 CMS
Incyte Corporation $2,055.0009/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226031893 CMS
Incyte Corporation $5,480.0009/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226169423 CMS
Rigel Pharmaceuticals, Inc. $118.6809/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247367991 CMS
Rigel Pharmaceuticals, Inc. $51.8509/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247367994 CMS
Incyte Corporation $18.7508/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226168893 CMS
Incyte Corporation $32.0008/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226168899 CMS
Incyte Corporation $686.9608/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226169257 CMS
Incyte Corporation $301.9708/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226169813 CMS
Incyte Corporation $28.4208/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226170025 CMS
Sumitomo Pharma America, Inc. $2,580.0008/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1176644555 CMS
Incyte Corporation $2,055.0008/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226042044 CMS
Daiichi Sankyo Inc. $967.5008/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1197089485 CMS
SERVIER PHARMACEUTICALS LLC $6,460.0007/25/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1229098878 CMS
SERVIER PHARMACEUTICALS LLC $1,020.0007/18/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1229098899 CMS
SERVIER PHARMACEUTICALS LLC $779.4007/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1229098886 CMS
SERVIER PHARMACEUTICALS LLC $1,177.2607/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1229098891 CMS
Daiichi Sankyo Inc. $1,290.0007/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1197003441 CMS
Daiichi Sankyo Inc. $967.5006/30/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1197092629 CMS
Daiichi Sankyo Inc. $967.5006/30/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1197101591 CMS
Daiichi Sankyo Inc. $967.5006/30/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1197102659 CMS
Syndax Pharmaceuticals, Inc. $5,600.0006/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238990944 CMS
Syndax Pharmaceuticals, Inc. $1,354.5806/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238990940 CMS
Syndax Pharmaceuticals, Inc. $84.8906/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238990942 CMS
Incyte Corporation $2,055.0006/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226161205 CMS
Daiichi Sankyo Inc. $15.0706/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197011301 CMS
Incyte Corporation $5,480.0006/11/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226043452 CMS
Daiichi Sankyo Inc. $469.8105/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1197094129 CMS
Incyte Corporation $56.0005/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225994528 CMS
Incyte Corporation $136.2205/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226043460 CMS
Incyte Corporation $358.0405/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226043830 CMS
Incyte Corporation $442.3705/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226043968 CMS
Incyte Corporation $185.0005/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226044034 CMS
Incyte Corporation $185.0005/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226044356 CMS
Incyte Corporation $28.4205/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226044496 CMS
SERVIER PHARMACEUTICALS LLC $2,380.0005/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1229098827 CMS
Incyte Corporation $5,480.0005/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226043466 CMS
Daiichi Sankyo Inc. $967.5005/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1197013021 CMS
Daiichi Sankyo Inc. $967.5005/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1197087999 CMS
Incyte Corporation $77.9505/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226043454 CMS
Incyte Corporation $187.6205/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226043826 CMS
Incyte Corporation $42.0005/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226043828 CMS
Incyte Corporation $515.2305/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226043832 CMS
Incyte Corporation $28.4205/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226043836 CMS
Incyte Corporation $673.3605/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226043838 CMS
Incyte Corporation $1,370.0004/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226110739 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $238,290.69 206
PY2020 $157,951.83 92
PY2021 $123,603.20 81
PY2022 $110,217.13 92
PY2023 $140,206.34 103
PY2024 $151,795.91 133
PY2025 $187,022.43 138

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $279,572.24 48
PY2024 Principal investigator $755,401.20 77
PY2023 Principal investigator $268,862.14 53
PY2022 Recipient $1,800.00 1
PY2022 Principal investigator $171,827.19 6
PY2021 Principal investigator $587,393.40 24
PY2020 Recipient $98,454.00 3
PY2020 Principal investigator $820,938.26 16
PY2019 Recipient $87,278.32 5
PY2019 Principal investigator $145,604.67 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Sumitomo Pharma America, Inc. $10,996.85 12/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176658017
Principal investigator 1 Daiichi Sankyo Inc. $18,000.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317455
Principal investigator 1 Daiichi Sankyo Inc. $4,788.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317457
Principal investigator 1 Daiichi Sankyo Inc. $332.50 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317459
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317461
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317463
Principal investigator 1 Daiichi Sankyo Inc. $4,250.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317465
Principal investigator 1 Daiichi Sankyo Inc. $700.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317467
Principal investigator 1 Daiichi Sankyo Inc. $446.90 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317469
Principal investigator 1 Daiichi Sankyo Inc. $1,244.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317471
Principal investigator 1 Daiichi Sankyo Inc. $1,955.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317473
Principal investigator 1 Sumitomo Pharma America, Inc. $209.83 12/11/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176657053
Principal investigator 1 Sumitomo Pharma America, Inc. $24,458.70 12/11/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176657057
Principal investigator 1 Sumitomo Pharma America, Inc. $2,197.56 12/11/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176657061
Principal investigator 1 Sumitomo Pharma America, Inc. $452.20 12/11/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176657063
Principal investigator 1 Sumitomo Pharma America, Inc. $1,453.75 12/11/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176657070
Principal investigator 1 Sumitomo Pharma America, Inc. $9,975.00 12/04/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176656933
Principal investigator 1 Sumitomo Pharma America, Inc. $1,643.69 12/04/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176656937
Principal investigator 1 Sumitomo Pharma America, Inc. $31,321.30 12/04/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176656941
Principal investigator 1 Sumitomo Pharma America, Inc. $1,452.35 12/04/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176656945
Principal investigator 1 Sumitomo Pharma America, Inc. $3,963.20 12/04/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176656949
Principal investigator 1 Sumitomo Pharma America, Inc. $21,758.80 12/04/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176657005
Principal investigator 1 Sumitomo Pharma America, Inc. $1,228.91 12/04/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176657008
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,330.00 12/01/2025 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes No dispute reported 06/30/2026 1250217979
Principal investigator 1 Agios Pharmaceuticals, Inc. $5,051.00 12/01/2025 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes No dispute reported 06/30/2026 1250218239
Principal investigator 1 TAIHO ONCOLOGY, INC. $3,963.00 09/01/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418335
Principal investigator 1 TAIHO ONCOLOGY, INC. $3,551.00 09/01/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211420481
Principal investigator 1 TAIHO ONCOLOGY, INC. $5,293.00 09/01/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211420483
Principal investigator 1 Sumitomo Pharma America, Inc. $1,468.63 07/24/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176641301
Principal investigator 1 Sumitomo Pharma America, Inc. $13,300.00 07/24/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176641305
Principal investigator 1 Sumitomo Pharma America, Inc. $3,232.41 07/17/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176640698
Principal investigator 1 Sumitomo Pharma America, Inc. $16,545.20 07/17/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176640702
Principal investigator 1 TAIHO ONCOLOGY, INC. $226.00 06/20/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419749
Principal investigator 1 Sumitomo Pharma America, Inc. $800.66 06/05/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176636129
Principal investigator 1 Sumitomo Pharma America, Inc. $10,477.50 06/05/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176636133
Principal investigator 1 Sumitomo Pharma America, Inc. $500.00 05/09/2025 Non-covered Recipient Entity
DUKE ABMT CLINIC
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176634648
Principal investigator 1 Sumitomo Pharma America, Inc. $3,762.89 04/24/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176633719
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,655.81 04/07/2025 Covered Recipient Teaching Hospital
Duke University Hospital
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) No dispute reported 06/30/2026 1236001294
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,476.00 03/19/2025 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes No dispute reported 06/30/2026 1250218057
Principal investigator 1 TAIHO ONCOLOGY, INC. $8,618.00 03/19/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419747
Principal investigator 1 Sumitomo Pharma America, Inc. $1,596.00 02/27/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176628681
Principal investigator 1 Sumitomo Pharma America, Inc. $4,655.00 02/27/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176628689
Principal investigator 1 Sumitomo Pharma America, Inc. $8,857.60 02/27/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176628693
Principal investigator 1 Sumitomo Pharma America, Inc. $46.00 02/27/2025 Non-covered Recipient Entity
DUKE ABMT CLINIC
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176628703
Principal investigator 1 Agios Pharmaceuticals, Inc. $4,825.00 02/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes No dispute reported 06/30/2026 1250217142
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,330.00 02/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes No dispute reported 06/30/2026 1250217370
Principal investigator 1 Agios Pharmaceuticals, Inc. $3,963.00 02/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes No dispute reported 06/30/2026 1250217372
Principal investigator 1 Novartis Pharmaceuticals Corporation $220.00 01/01/2025 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy No dispute reported 06/30/2026 1190305929